[1]雷秋萍,曹建,李晓庆,等.小婴儿先天性巨结肠肠造瘘的危险因素分析[J].第三军医大学学报,2020,42(12):1215-1219.
 LEI Qiuping,CAO Jian,LI Xiaoqing,et al.Analysis of risk factors of enterostomy in infants with Hirschsprung’s disease[J].J Third Mil Med Univ,2020,42(12):1215-1219.
点击复制

小婴儿先天性巨结肠肠造瘘的危险因素分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
42卷
期数:
2020年第12期
页码:
1215-1219
栏目:
临床医学
出版日期:
2020-06-30

文章信息/Info

Title:
Analysis of risk factors of enterostomy in infants with Hirschsprung’s disease
作者:
雷秋萍曹建李晓庆周德凯王佚何昀
重庆医科大学附属儿童医院胃肠新生儿外科;儿童发育疾病研究教育部重点实验室;国家儿童健康与疾病临床医学研究中心; 儿童发育重大疾病国家国际科技合作基地; 儿科学重庆市重点实验室
 
Author(s):
LEI Qiuping CAO Jian LI Xiaoqing ZHOU Dekai WANG Yi HE Yun

Department of Neonatal Gastrointestinal Surgery, Key Laboratory of Child Development and Disorders of Ministry of Education, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Children’s Hospital of Chongqing Medical University, Chongqing, 400014, China

关键词:
先天性巨结肠肠造瘘术危险因素小婴儿  
Keywords:
Hirschsprung&rsquos disease enterostomy risk factors infants  
分类号:
R181.32;R725.746.2;R726.569
文献标志码:
A
摘要:

目的探讨小婴儿先天性巨结肠肠造瘘的危险因素,为临床工作者做出适时判断提供参考,并提高对治疗时机的把握。方法回顾性分析2013年1月至2019年1月重庆医科大学附属儿童医院收治的201例小婴儿先天性巨结肠临床资料,通过单因素和多因素Logistic回归分析患儿一般资料、临床表现及实验室检验结果,总结分析肠造瘘的危险因素。结果本组肠造瘘发生率22.4%,经多因素Logistic回归分析发现血清白蛋白降低(OR值=0.737,95%CI=0.633~0.857,P=0.000),大便常规异常(OR值=10.634,95%CI=3.016~37.502,P=0.000),PCT>2 ng/mL(OR值=9.954,95%CI=2.517~39.368,P=0.001),右侧型先天性巨结肠(OR值=4.307,95%CI=1.417~13.092,P=0.010)为本组患儿肠造瘘的危险因素。结论血清白蛋白降低、大便常规异常、PCT>2 ng/mL以及右侧型先天性巨结肠为小婴儿先天性巨结肠肠造瘘的危险因素。
 

Abstract:

ObjectiveTo explore the risk factors of enterostomy in infants with Hirschsprung’s disease (HSCR) to facilitate timely evaluation of the condition and the clinical decision-making on the timing of intervention. MethodsWe retrospectively analyzed the data of 201 infants diagnosed with HSCR in our hospital between January, 2013 and January, 2019. Univariate analysis and multivariate logistic regression were used to analyze the clinical data and laboratory test results of the patients to identify the risk factors of enterostomy. ResultsThe incidence of enterostomy was 22.4% in these infants. Multivariate logistic regression analysis showed that lowered serum albumin level (OR=0.737, 95% CI: 0.633-0.857, P=0.000), abnormal stool routine (OR=10.634, 95% CI: 3.016-37.502, P=0.000), procalcitonin (PCT) level >2 ng/mL (OR=9.954, 95% CI: 2.517-39.368, P=0.001), and right-sided HSCR (OR=4.307, 95% CI: 1.417-13.092, P=0.010) were risk factors for enterostomy in infants. ConclusionA lowed serum albumin level, abnormal stool routine, a PCT level >2 ng/mL and right-sided HSCR are risk factors for enterostomy in infants with HSCR.
 

参考文献/References:

[1]WANG J X, DAHAL G R. Hirschsprung’s disease management: from multi staged operation to single staged transanal pull-through[J]. Nepal Med Coll J, 2009, 11(2): 138-142.

[2]SULKOWSKI J P, COOPER J N, CONGENI A, et al. Single-stage versus multi-stage pull-through for Hirschsprung’s disease: practice trends and outcomes in infants[J]. J Pediatr Surg, 2014, 49(11): 1619-1625. DOI: 10.1016/j.jpedsurg.2014.06.002.

[3]BRADNOCK T J, WALKER G M. Evolution in the management of Hirschsprung’s disease in the UK and Ireland: a national survey of practice revisited[J]. Ann R Coll Surg Engl, 2011, 93(1): 34-38. DOI: 10.1308/003588410X12771 863936846.

[4]中华医学会小儿外科学分会肛肠学组、新生儿学组. 先天性巨结肠的诊断及治疗专家共识[J]. 中华小儿外科杂志, 2017, 38(11): 805-815. DOI: 10.3760/cma.j.issn.0253-3006.2017.11.002.

Anorectum and Neonatology Group of Pediatric Surgery Branch of Chinese Medical Association.The guidelines of diagnosis and treatment of Hirschspung’s disease[J]. Chin J Pediatr Surg, 2017, 38(11): 805-815. DOI: 10.3760/cma.j.issn.0253-3006.2017.11.002.

[5]THAKKAR H S, BLACKBURN S, CURRY J, et al. Variability of the transition zone length in Hirschsprung disease[J]. J Pediatr Surg, 2020, 55(1): 63-66. DOI: 10.1016/j.jpedsurg.2019.09.056.

[6]BRADNOCK T J, KNIGHT M, KENNY S, et al. The use of stomas in the early management of Hirschsprung disease: Findings of a national, prospective cohort study[J]. J Pediatr Surg, 2017, 52(9): 1451-1457. DOI: 10.1016/j.jpedsurg.2017.05.008.

[7]DAS K, MOHANTY S.Hirschsprung disease—current diagnosis and management[J]. Indian J Pediatr, 2017, 84(8): 618-623. DOI: 10.1007/s12098-017-2371-8.

[8]TANG J, LIU X, MA T S, et al. Application of enhanced recovery after surgery during the perioperative period in infants with Hirschsprung’s disease—A multi-center randomized clinical trial[J]. Clin Nutr, 2019: S0261-S5614(19)33072-9. DOI: 10.1016/j.clnu.2019.10.001.

[9]KELLER U. Nutritional laboratory markers inmalnutrition[J]. J Clin Med, 2019, 8(6): E775. DOI: 10.3390/jcm8060775.

[10]WESSNER S, BURJONRAPPA S. Review of nutritional assessment and clinical outcomes in pediatric surgical patients: does preoperative nutritional assessment impact clinical outcomes?[J]. J Pediatr Surg, 2014, 49(5): 823-830. DOI: 10.1016/j.jpedsurg.2014.01.006.

[11]CHUNG P H Y, YU M O N, WONG KK Y, et al. Risk factors for the development of post-operative enterocolitis in short segment Hirschsprung’s disease[J]. Pediatr Surg Int, 2019, 35(2): 187-191. DOI: 10.1007/s00383-018-4393-3.

[12]AUSTIN K M. The pathogenesis of Hirschsprung’s disease-associated enterocolitis[J]. Semin Pediatr Surg, 2012, 21(4): 319-327. DOI: 10.1053/j.sempedsurg.2012.07.006.

[13]WEN Q P, LIU K Z, YUE W H, et al. Clinical significance of positive fecal occult blood test in neonates[J]. Sci Rep, 2019, 9: 17898. DOI: 10.1038/s41598-019-54511-5.

[14]GOSAIN A, FRYKMAN P K, COWLES R A, et al. Guidelines for the diagnosis and management of Hirschsprung-associated enterocolitis[J]. Pediatr Surg Int, 2017, 33(5): 517-521. DOI: 10.1007/s00383-017-4065-8.

[15]FRYKMAN P K, SHORT SS. Hirschsprung-associated enterocolitis: prevention and therapy[J]. Semin Pediatr Surg, 2012, 21(4): 328-335. DOI: 10.1053/j.sempedsurg.2012.07.007.

[16]MURPHY F, PURI P. New insights into the pathogenesis of Hirschsprung’s associated enterocolitis[J]. Ped Surgery Int, 2005, 21(10): 773-779. DOI: 10.1007/s00383-005-1551-1.

[17]GOLDSTEIN G P, SYLVESTER K G. Biomarker discovery and utility in necrotizing enterocolitis[J]. Clin Perinatol, 2019, 46(1): 1-17. DOI: 10.1016/j.clp.2018.10.001.

[18]SHAPIRO D, FRIEDMANN R, HUSSEINI A, et al. Can procalcitonin contribute to the diagnosis of clostridium difficile colitis?[J]. Isr Med Assoc J. 2017, 19(5): 313-316.

[19]DE JONG E, VAN OERS J A, BEISHUIZEN A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial[J]. Lancet Infect Dis, 2016, 16(7): 819-827. DOI: 10.1016/s1473-3099(16)00053-0.

[20]TRSY D, TNCZOS K, NMETH M, et al. Early pro-calcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients[J]. J Crit Care, 2016, 34: 50-55. DOI: 10.1016/j.jcrc.2016.04.007.

[21]YAN J Y, CHEN Y W, DING C L, et al. Clinical outcomes after staged and primary laparotomy Soave procedure for total colonic aganglionosis: a single-center experience from 2007 to 2017[J]. J Gastrointest Surg, 2019. [Epub ahead of print]. DOI: 10.1007/s11605-019-04319-5.

更新日期/Last Update: 2020-06-19